Salvage treatment of unfavorable non-Hodgkin's lymphoma with cisplatin, amsacrine, and mitoguazone: a Southwest Oncology Group Pilot Study

We tested the combination of cisplatin, amsacrine, and mitoguazone as salvage treatment for patients with advanced unfavorable non-Hodgkin's lymphomas. An objective response rate of 43% was noted in 30 evaluable patients, but all responses were partial and the median duration of response was on...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer treatment reports Vol. 70; no. 2; p. 291
Main Authors:	Dana, B W, Jones, S E, Coltman, C, Stuckey, W J
Format:	Journal Article
Language:	English
Published:	United States 01-02-1986
Subjects:	Adult Aged Aminoacridines - administration & dosage Amsacrine Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cisplatin - administration & dosage Digestive System - drug effects Female Humans Leukopenia - chemically induced Lymphoma - drug therapy Male Middle Aged Mitoguazone - administration & dosage
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	We tested the combination of cisplatin, amsacrine, and mitoguazone as salvage treatment for patients with advanced unfavorable non-Hodgkin's lymphomas. An objective response rate of 43% was noted in 30 evaluable patients, but all responses were partial and the median duration of response was only 2 months. Toxicity included life-threatening and fatal leukopenia and severe gastrointestinal intolerance. We conclude that this combination chemotherapy regimen is not a valuable salvage treatment for patients with non-Hodgkin's lymphoma.
ISSN:	0361-5960